These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36552803)

  • 1. RNA-Seq of Dermal Fibroblasts from Patients with Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders Supports Their Categorization as a Single Entity with Involvement of Extracellular Matrix Degrading and Proinflammatory Pathomechanisms.
    Ritelli M; Chiarelli N; Cinquina V; Zoppi N; Bertini V; Venturini M; Colombi M
    Cells; 2022 Dec; 11(24):. PubMed ID: 36552803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermal fibroblast-to-myofibroblast transition sustained by αvß3 integrin-ILK-Snail1/Slug signaling is a common feature for hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders.
    Zoppi N; Chiarelli N; Binetti S; Ritelli M; Colombi M
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt A):1010-1023. PubMed ID: 29309923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix Metalloproteinases Inhibition by Doxycycline Rescues Extracellular Matrix Organization and Partly Reverts Myofibroblast Differentiation in Hypermobile Ehlers-Danlos Syndrome Dermal Fibroblasts: A Potential Therapeutic Target?
    Chiarelli N; Zoppi N; Venturini M; Capitanio D; Gelfi C; Ritelli M; Colombi M
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological insights in the pathogenesis of hypermobile Ehlers-Danlos syndrome from proteome profiling of patients' dermal myofibroblasts.
    Chiarelli N; Zoppi N; Ritelli M; Venturini M; Capitanio D; Gelfi C; Colombi M
    Biochim Biophys Acta Mol Basis Dis; 2021 Apr; 1867(4):166051. PubMed ID: 33383104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifaced Roles of the αvβ3 Integrin in Ehlers-Danlos and Arterial Tortuosity Syndromes' Dermal Fibroblasts.
    Zoppi N; Chiarelli N; Ritelli M; Colombi M
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Looking back and beyond the 2017 diagnostic criteria for hypermobile Ehlers-Danlos syndrome: A retrospective cross-sectional study from an Italian reference center.
    Ritelli M; Chiarelli N; Cinquina V; Vezzoli M; Venturini M; Colombi M
    Am J Med Genet A; 2024 Feb; 194(2):174-194. PubMed ID: 37774134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermobile Ehlers-Danlos syndrome and disorders of the gastrointestinal tract: What the gastroenterologist needs to know.
    Thwaites PA; Gibson PR; Burgell RE
    J Gastroenterol Hepatol; 2022 Sep; 37(9):1693-1709. PubMed ID: 35750466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermobile Ehlers-Danlos syndromes: Complex phenotypes, challenging diagnoses, and poorly understood causes.
    Gensemer C; Burks R; Kautz S; Judge DP; Lavallee M; Norris RA
    Dev Dyn; 2021 Mar; 250(3):318-344. PubMed ID: 32629534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing a self-management intervention to manage hypermobility spectrum disorders (HSD) and hypermobile Ehlers-Danlos syndrome (hEDS): an analysis informed by behaviour change theory.
    Bennett SE; Walsh N; Moss T; Palmer S
    Disabil Rehabil; 2022 Sep; 44(18):5231-5240. PubMed ID: 34101520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare experiences among adults with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder in the United States.
    Estrella E; Frazier PA
    Disabil Rehabil; 2024 Feb; 46(4):731-740. PubMed ID: 36772820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of patients with hypermobile type Ehlers-Danlos syndrome (hEDS) and generalized hypermobility spectrum disorders (G-HSD): an online survey.
    Teran-Wodzinski P; Kumar A
    Rheumatol Int; 2023 Oct; 43(10):1935-1945. PubMed ID: 37378685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptome-Wide Expression Profiling in Skin Fibroblasts of Patients with Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome Hypermobility Type.
    Chiarelli N; Carini G; Zoppi N; Dordoni C; Ritelli M; Venturini M; Castori M; Colombi M
    PLoS One; 2016; 11(8):e0161347. PubMed ID: 27518164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional neurological signs in hypermobile Ehlers-Danlos syndrome and hypermobile spectrum disorders with suspected neuropathic pain.
    Fernandez A; Jaquet M; Aubry-Rozier B; Suter M; Aybek S; Berna C
    Brain Behav; 2024 Feb; 14(2):e3441. PubMed ID: 38409931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history.
    Tinkle B; Castori M; Berglund B; Cohen H; Grahame R; Kazkaz H; Levy H
    Am J Med Genet C Semin Med Genet; 2017 Mar; 175(1):48-69. PubMed ID: 28145611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mast cell activation disease and immunoglobulin deficiency in patients with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorder.
    Brock I; Prendergast W; Maitland A
    Am J Med Genet C Semin Med Genet; 2021 Dec; 187(4):473-481. PubMed ID: 34747107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ehlers-Danlos Syndromes, Joint Hypermobility and Hypermobility Spectrum Disorders.
    Micale L; Fusco C; Castori M
    Adv Exp Med Biol; 2021; 1348():207-233. PubMed ID: 34807421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and Molecular Mechanisms in the Pathogenesis of Classical, Vascular, and Hypermobile Ehlers‒Danlos Syndromes.
    Chiarelli N; Ritelli M; Zoppi N; Colombi M
    Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31409039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subtle differences in autonomic symptoms in people diagnosed with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders.
    Martinez KL; Mauss C; Andrews J; Saboda K; Huynh JM; Sanoja AJ; Jesudas R; Byers PH; Laukaitis CM
    Am J Med Genet A; 2021 Jul; 185(7):2012-2025. PubMed ID: 33826221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are patients with hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder so different?
    Aubry-Rozier B; Schwitzguebel A; Valerio F; Tanniger J; Paquier C; Berna C; Hügle T; Benaim C
    Rheumatol Int; 2021 Oct; 41(10):1785-1794. PubMed ID: 34398260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical therapy interventions in generalized hypermobility spectrum disorder and hypermobile Ehlers-Danlos syndrome: a scoping review.
    Garreth Brittain M; Flanagan S; Foreman L; Teran-Wodzinski P
    Disabil Rehabil; 2024 May; 46(10):1936-1953. PubMed ID: 37231592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.